Forbes J M & Co. LLP Has $16.61 Million Stock Holdings in Zoetis Inc (NYSE:ZTS)

Forbes J M & Co. LLP boosted its position in shares of Zoetis Inc (NYSE:ZTS) by 11.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 146,325 shares of the company’s stock after purchasing an additional 14,567 shares during the quarter. Zoetis comprises 3.2% of Forbes J M & Co. LLP’s holdings, making the stock its 4th biggest position. Forbes J M & Co. LLP’s holdings in Zoetis were worth $16,606,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its position in shares of Zoetis by 2.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after purchasing an additional 39,319 shares during the period. Raymond James & Associates grew its position in shares of Zoetis by 5.9% in the 1st quarter. Raymond James & Associates now owns 862,600 shares of the company’s stock valued at $86,839,000 after purchasing an additional 48,065 shares during the period. WealthPLAN Partners LLC grew its position in shares of Zoetis by 6.9% in the 1st quarter. WealthPLAN Partners LLC now owns 4,162 shares of the company’s stock valued at $424,000 after purchasing an additional 268 shares during the period. Decatur Capital Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $5,462,000. Finally, Greenleaf Trust grew its position in shares of Zoetis by 9.0% in the 2nd quarter. Greenleaf Trust now owns 3,811 shares of the company’s stock valued at $433,000 after purchasing an additional 315 shares during the period. 90.08% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Kristin C. Peck sold 11,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $123.22, for a total value of $1,417,030.00. Following the sale, the executive vice president now owns 48,877 shares in the company, valued at approximately $6,022,623.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Heidi C. Chen sold 2,500 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $104.23, for a total value of $260,575.00. Following the completion of the sale, the insider now owns 11,463 shares in the company, valued at approximately $1,194,788.49. The disclosure for this sale can be found here. In the last three months, insiders sold 38,969 shares of company stock valued at $4,520,953. 0.29% of the stock is currently owned by insiders.



Shares of NYSE ZTS traded up $1.39 during trading hours on Friday, hitting $125.07. The company had a trading volume of 239,157 shares, compared to its average volume of 2,011,880. The stock has a market capitalization of $59.55 billion, a P/E ratio of 39.96, a price-to-earnings-growth ratio of 3.15 and a beta of 0.92. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. Zoetis Inc has a 1-year low of $78.90 and a 1-year high of $125.88. The firm’s 50 day moving average is $116.31 and its 200-day moving average is $104.22.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.82 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. On average, sell-side analysts predict that Zoetis Inc will post 3.57 earnings per share for the current year.

A number of equities analysts have weighed in on ZTS shares. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. SunTrust Banks upped their price target on Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday. Stifel Nicolaus upped their price target on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Barclays upped their price target on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and upped their price target for the stock from $111.00 to $120.00 in a research report on Monday, July 1st. They noted that the move was a valuation call. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $115.13.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Price Target

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.